Vertex Pharmaceuticals Incorporated (VRTX) Stock Analysis
Last updated Oct 27, 2026
Health Check
Last analyzed Oct 23, 2026
- Financial Health 85
- Profitability 60
- Business Quality 100
- Balance Sheet 65
- Cash Flow 60
Why this rating?
Health 76/100 — Elite Quality
Worth tracking, but timing is mixed — not a clear setup yet.
Company overview
Vertex Pharmaceuticals Incorporated (VRTX) is a Biotechnology company in the Healthcare sector. Compound Radar rates Vertex Pharmaceuticals Incorporated 76/100 (Elite Quality) due to high business quality, steady revenue growth, and manageable leverage.
Investment profile
- Quality High
- Growth Moderate
- Balance Sheet Adequate
- Valuation Fair
Financial highlights
Valuation
- P/E 30.35
- Forward P/E 25.54
- PEG 2.02
- EV/Revenue 9.95
Profitability
- Revenue Growth 12.5%
- Gross Margin 55.0%
- Operating Margin 38.1%
- Net Margin 35.0%
- ROE 23.5%
Financial strength
- Cash $7.85B
- Debt $1.98B
- Net Cash $5.87B
- Free Cash Flow $3.19B
- Current Ratio 3.19
Similar companies
Peers in Biotechnology, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Aurinia Pharmaceuticals Inc. Biotechnology AUPH$17.25 83 Health 83 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Incyte Corporation Biotechnology INCY$116.60 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Catalyst Pharmaceuticals Inc Biotechnology CPRX$31.49 81 Health 81 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- ADMA Biologics, Inc. Biotechnology ADMA$11.06 80 Health 80 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Innoviva, Inc. Biotechnology INVA$20.94 80 Health 80 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Strong Entry Strong EntryTiming looks favorable across trend, momentum, valuation, support, and catalysts.
- Alnylam Pharmaceuticals, Inc. Biotechnology ALNY$226.79 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Halozyme Therapeutics, Inc. Biotechnology HALO$128.50 77 Health 77 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Harmony Biosciences Holdings, Inc. Biotechnology HRMY$37.95 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Vertex Pharmaceuticals Incorporated (VRTX).